These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 34827004)

  • 1. Assessment of the lamina cribrosa in attention-deficit hyperactivity disorder.
    Akkaya S; Ulusoy DM; Doğan H; Arslan ME
    Indian J Ophthalmol; 2021 Dec; 69(12):3607-3611. PubMed ID: 34827004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
    Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S
    CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of methylphenidate on body index and physical fitness in Korean children with attention deficit hyperactivity disorder.
    Kang KD; Yun SW; Chung U; Kim TH; Park JH; Park IH; Han DH
    Hum Psychopharmacol; 2016 Mar; 31(2):76-82. PubMed ID: 26756111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methylphenidate versus dexamphetamine in children with attention deficit hyperactivity disorder: A double-blind, crossover trial.
    Efron D; Jarman F; Barker M
    Pediatrics; 1997 Dec; 100(6):E6. PubMed ID: 9382907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Empathy and Facial Expression Recognition in Children With and Without Attention-Deficit/Hyperactivity Disorder: Effects of Stimulant Medication on Empathic Skills in Children with Attention-Deficit/Hyperactivity Disorder.
    Gumustas F; Yilmaz I; Yulaf Y; Gokce S; Sabuncuoglu O
    J Child Adolesc Psychopharmacol; 2017 Jun; 27(5):433-439. PubMed ID: 28332851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of HLD200, Delayed-Release and Extended-Release Methylphenidate, in Children with Attention-Deficit/Hyperactivity Disorder.
    Pliszka SR; Wilens TE; Bostrom S; Arnold VK; Marraffino A; Cutler AJ; López FA; DeSousa NJ; Sallee FR; Incledon B; Newcorn JH
    J Child Adolesc Psychopharmacol; 2017 Aug; 27(6):474-482. PubMed ID: 29172680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Choroidal Vascular Index in Patients With Attention-Deficit/Hyperactivity Disorder and Methylphenidate.
    Kiziltoprak H; Kocabas DO; Aydemir GA; Kalınlı EM; Aydemir E; Oren B
    J Pediatr Ophthalmol Strabismus; 2023; 60(6):411-416. PubMed ID: 36546779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized controlled trial of osmotic-release methylphenidate with cognitive-behavioral therapy in adolescents with attention-deficit/hyperactivity disorder and substance use disorders.
    Riggs PD; Winhusen T; Davies RD; Leimberger JD; Mikulich-Gilbertson S; Klein C; Macdonald M; Lohman M; Bailey GL; Haynes L; Jaffee WB; Haminton N; Hodgkins C; Whitmore E; Trello-Rishel K; Tamm L; Acosta MC; Royer-Malvestuto C; Subramaniam G; Fishman M; Holmes BW; Kaye ME; Vargo MA; Woody GE; Nunes EV; Liu D
    J Am Acad Child Adolesc Psychiatry; 2011 Sep; 50(9):903-14. PubMed ID: 21871372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Remission in children and adolescents diagnosed with attention-deficit/hyperactivity disorder via an effective and tolerable titration scheme for osmotic release oral system methylphenidate.
    Chou WJ; Chen SJ; Chen YS; Liang HY; Lin CC; Tang CS; Huang YS; Yeh CB; Chou MC; Lin DY; Hou PH; Wu YY; Liu HJ; Huang YF; Hwang KL; Chan CH; Pan CH; Chang HL; Huang CF; Hsu JW
    J Child Adolesc Psychopharmacol; 2012 Jun; 22(3):215-25. PubMed ID: 22537358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of OROS methylphenidate on encopresis in children with attention-deficit/hyperactivity disorder.
    Yılmaz S; Bilgiç A; Hergüner S
    J Child Adolesc Psychopharmacol; 2014 Apr; 24(3):158-60. PubMed ID: 24168715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Possible Effect of Methylphenidate Treatment on Empathy in Children Diagnosed with Attention-Deficit/Hyperactivity Disorder, Both With and Without Comorbid Oppositional Defiant Disorder.
    Golubchik P; Weizman A
    J Child Adolesc Psychopharmacol; 2017 Jun; 27(5):429-432. PubMed ID: 28398816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Attention-deficit/hyperactivity disorder and comorbid subsyndromal depression: what is the impact of methylphenidate on mood?
    Golubchik P; Kodesh A; Weizman A
    Clin Neuropharmacol; 2013; 36(5):141-5. PubMed ID: 24045603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimization of Methylphenidate Extended-Release Chewable Tablet Dose in Children with ADHD: Open-Label Dose Optimization in a Laboratory Classroom Study.
    Wigal SB; Childress A; Berry SA; Belden HW; Chappell P; Wajsbrot DB; Nagraj P; Abbas R; Palumbo D
    J Child Adolesc Psychopharmacol; 2018 Jun; 28(5):314-321. PubMed ID: 29641237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improvements in Irritability with Open-Label Methylphenidate Treatment in Youth with Comorbid Attention Deficit/Hyperactivity Disorder and Disruptive Mood Dysregulation Disorder.
    Winters DE; Fukui S; Leibenluft E; Hulvershorn LA
    J Child Adolesc Psychopharmacol; 2018 Jun; 28(5):298-305. PubMed ID: 29708762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomised, placebo-controlled, 24-week, study of low-dose extended-release methylphenidate in adults with attention-deficit/hyperactivity disorder.
    Rösler M; Fischer R; Ammer R; Ose C; Retz W
    Eur Arch Psychiatry Clin Neurosci; 2009 Mar; 259(2):120-9. PubMed ID: 19165529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Open-Label Dose Optimization of Methylphenidate Extended-Release Orally Disintegrating Tablet in a Laboratory Classroom Study of Children with Attention-Deficit/Hyperactivity Disorder.
    Childress AC; Kollins SH; Cutler AJ; Marraffino A; Sikes CR
    J Child Adolesc Psychopharmacol; 2021 Jun; 31(5):342-349. PubMed ID: 34081560
    [No Abstract]   [Full Text] [Related]  

  • 17. Attention-deficit/hyperactivity disorder with obstructive sleep apnea: a treatment outcome study.
    Huang YS; Guilleminault C; Li HY; Yang CM; Wu YY; Chen NH
    Sleep Med; 2007 Jan; 8(1):18-30. PubMed ID: 17157069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Levels of Proneness to Boredom in Children with Attention-Deficit/Hyperactivity Disorder On and Off Methylphenidate Treatment.
    Golubchik P; Manor I; Shoval G; Weizman A
    J Child Adolesc Psychopharmacol; 2020 Apr; 30(3):173-176. PubMed ID: 32031873
    [No Abstract]   [Full Text] [Related]  

  • 19. Better efficacy for the osmotic release oral system methylphenidate among poor adherents to immediate-release methylphenidate in the three ADHD subtypes.
    Chou WJ; Chou MC; Tzang RF; Hsu YC; Gau SS; Chen SJ; Wu YY; Huang YF; Liang HY; Cheng H
    Psychiatry Clin Neurosci; 2009 Apr; 63(2):167-75. PubMed ID: 19335386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mood and Proneness to Boredom Are Associated with Poorer Continuous Performance Test Results, Which May Improve with Methylphenidate Treatment, in Attention-Deficit/Hyperactivity Disorder.
    Golubchik P; Schoen G; Weizman A
    J Child Adolesc Psychopharmacol; 2021 May; 31(4):310-314. PubMed ID: 33956509
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.